{"id":11451,"date":"2011-02-28T00:00:00","date_gmt":"2011-02-27T23:00:00","guid":{"rendered":"https:\/\/idibell.cat\/es\/blog\/2011\/02\/28\/descubren-una-sustancia-que-actua-contra-el-genoma-oscuro-del-cancer\/"},"modified":"2020-05-26T15:51:02","modified_gmt":"2020-05-26T13:51:02","slug":"descubren-una-sustancia-que-actua-contra-el-genoma-oscuro-del-cancer","status":"publish","type":"post","link":"https:\/\/idibell.cat\/es\/2011\/02\/descubren-una-sustancia-que-actua-contra-el-genoma-oscuro-del-cancer\/","title":{"rendered":"Descubren una sustancia que act\u00faa contra el \u2018genoma oscuro\u2019 del c\u00e1ncer"},"content":{"rendered":"

Un estudio coordinado por el investigador Manel Esteller, investigador ICREA del IDIBELL, ha identificado una sustancia que inhibe el crecimiento del c\u00e1ncer mediante la activaci\u00f3n del llamado \u201cgenoma oscuro\u201d (o ADN no-codificante) y de las mol\u00e9culas de micro-ARN. El estudio se publica esta semana en la prestigiosa revista cient\u00edfica
<\/span>Proceedings of the National Academy of Sciences (PNAS)<\/span><\/a>.<\/span>
Las c\u00e9lulas del cuerpo humano poseen un genoma (el conjunto de nuestro ADN) que codifica nuestras prote\u00ednas, como la queratina de la piel o la hemoglobina de la sangre. Este genoma con ADN codificando s\u00f3lo representa el 5% de nuestro material gen\u00e9tico. El 95% restante se conoce como genoma oscuro o ADN no-codificante y su funci\u00f3n es en buena parte desconocida. Una parte de este ADN produce unas peque\u00f1as mol\u00e9culas denominadas microARN encargadas de activar o desactivar los genes. En los \u00faltimos a\u00f1os se ha demostrado que alteraciones en estas mol\u00e9culas est\u00e1n relacionadas con la formaci\u00f3n de tumores.
Enoxacina<\/strong>
<\/strong> Los investigadores han demostrado que la peque\u00f1a mol\u00e9cula enoxacina, utilizada en compuestos antibacterianos, se une a la prote\u00edna que construye los micro-ARN y estimula su actividad inhibidora del crecimiento del tumor. Seg\u00fan el investigador Manel Esteller \u201ces como si a un coche de segunda mano le ponemos un motor acabado de salir de la f\u00e1brica\u201d. Lo han comprobado tanto en c\u00e9lulas de laboratorio como en modelos experimentales animales y ahora deber\u00eda estudiarse su funcionamiento en humanos. As\u00ed lo ha dicho Esteller, que ha destacado que la ventaja de este compuesto es que se conoce su metabolismo y su seguridad en humanos. Esteller ha a\u00f1adido que \u201caunque pueda no llegar a aprobarse el uso de esta mol\u00e9cula en tratamientos oncol\u00f3gicos, el hallazgo obro la puerta al dise\u00f1o de nuevos f\u00e1rmacos que tengan como diana terap\u00e9utica los microARN. Mostramos a la industria farmac\u00e9utica una nueva direcci\u00f3n hacia d\u00f3nde dirigir sus esfuerzos en la terapia antitumoral\u201d.
Referencia del art\u00edculo<\/strong>
<\/strong> Sonia Melo*, Alberto Villanueva*, Catia Moutinho*, Ver\u00f3nica Davalos*, Ricardo Spizzo, Cristina Ivan , Simona Rossi, Fernando Setien*, Oriol Casanovas*, Laia Sio-Riudalbas*, Javier Carmona*, Jordi Carrere*, August Vidal*, \u00c1lvaro Aytes*, Sara Puertas*, Santiagio Ropero, Raghu Kalluri, Carlo M. Croce, George A. Calin, Manel Esteller*. The small molecule enoxacin is a cancer-specific growth inhibitor that acts by enhancing TRBP-mediated microRNA processing. Proceedings of the National Academy of Science USA (PNAS)<\/em>, Early Edition, February 28th<\/sup> 2011.<\/p>\n","protected":false},"excerpt":{"rendered":"

Enoxacina Referencia del art\u00edculo<\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"no-sidebar","site-content-layout":"page-builder","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[242,184,286,254,281,206],"tags":[],"class_list":["post-11451","post","type-post","status-publish","format-standard","hentry","category-angiogenesis-tumoral","category-area-cancer","category-epigenetica-del-cancer-cancer","category-mecanismos-de-resistencia-y-progresion-en-el-cancer-de-prostata","category-programa-de-mecanismos-moleculares-y-terapia-experimental-en-oncologia-oncobell","category-quimioresistencia-tumoral-y-estromal"],"publishpress_future_action":{"enabled":false,"date":"2024-12-25 20:13:52","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/posts\/11451","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/comments?post=11451"}],"version-history":[{"count":0,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/posts\/11451\/revisions"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/media?parent=11451"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/categories?post=11451"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/tags?post=11451"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}